Do MSH2 carriers benefit from hysterectomy or oophorectomy after 40?

For MSH2 carriers past 40, the evidence for hysterectomy and oophorectomy is based on risk modeling, not on trials that compare surgery to surveillance alone.

The retrieved studies do not include a single trial that randomizes MSH2 carriers to surgery versus surveillance and measures cancer incidence or mortality. What exists are observational data and expert opinion. One 2003 study of 41 women at risk for Lynch syndrome found that over 10 years of annual screening, no ovarian cancers were detected and one interval endometrial cancer occurred [1]. That is a small study, but it suggests screening catches some things and misses others.

The prospective data on risk is clearer. In MSH2 carriers who already had one cancer, the cumulative risk of any subsequent cancer by age 70 is about 76 in 100 [2]. Endometrial cancer risk specifically is high enough that the Uruguayan cohort paper recommends considering bilateral salpingo-oophorectomy and hysterectomy after childbearing [3]. But that recommendation is not backed by a trial showing it saves lives compared to surveillance.

A 2013 case report of a 44-year-old MSH2 carrier with endometriosis who developed synchronous endometrial and ovarian cancers illustrates the concern [4]. One case does not prove a rule, but it shows the mechanism: MSH2 carriers can develop multiple gynecologic cancers at once, and screening can miss them.

The evidence gap is real. No study in this retrieval measures how many cancers are prevented per 100 surgeries, or how many women would need surgery to prevent one death. The decision rests on the individual's tolerance for risk and the limits of surveillance, not on a proven net benefit from surgery.

My call: the evidence supports considering surgery after childbearing, but the benefit over surveillance alone is not proven in MSH2 carriers specifically. Confidence: low.